Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects

Not Applicable

Completed

• Conditions: Schizophrenia

• Registration Number: NCT00166322
• Lead Sponsor: Ludwig-Maximilians - University of Munich

Brief Summary

This study is an investigation of the dopaminergic neurotransmission in patients with schizophrenia, patients at risk for the development of schizophrenia, and healthy controls using an iodobenzamide-single photon emission computed tomography (IBZM-SPECT) imaging technique under amphetamine challenge.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-01
• Study First Submitted: 2005-09-09
• Study First Submitted QC: 2005-09-09
• Study First Posted: 2005-09-14
• Primary Completion: 2007-12
• Study Completion: 2007-12
• Status Verified: 2008-05
• Last Update Submitted: 2008-05-06
• Last Update Posted: 2008-05-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

• Clinical diagnosis of schizophrenia (currently unmedicated)
• Subjects at risk for the development of schizophrenia (prodromal symptoms)
• Healthy subjects
• Written informed consent

Exclusion Criteria

• Neurological or severe somatic disorders
• Women during pregnancy or lactation
• Occupational exposition to radiation > 15mSv
• Medication known to interfere with IBZM
• Contraindications for the use of amphetamine challenge

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
dopamine receptor availability	cross-sectional

Trial Locations

Locations (2)

Dept. of Psychiatry; 🇩🇪 Munich, Germany

Dept. of Nuclear Medicine; 🇩🇪 Munich, Germany